Scientist practitioners

Led by world-renowned experts, we can undertake health preference, health outcomes and health economic studies completely in-house, with bespoke survey development securely running on our own servers. Our team has developed methods and contributed to the development of guidance in the field of health preference research. We are known because of our knowledge of quantitative expertise and our solid track records of publications in scientific journals.


Some of our publications

Value in Health. 2020 Nov;23(11):1489-1496

Testing the "Nonstopping" Time Trade-Off: Is It Better Than the Composite Time Trade-Off?

Luo N, Augestad L, Rand K.

Journal of Patient-Reported Outcomes. 2020 Nov 9;4(1):92

Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L

Rand K, Arnevik EA, Walderhaug E.

Value in Health. 2020 Apr;23(4):487-494

Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match?

Augestad LA, Rand K, Luo N, Barra M.

BMC Health Services Research. 2019 Oct 16;19(1):705

Fewer ischemic strokes, despite an ageing population: stroke models from observed incidence in Norway 2010-2015

Rand K, Dahl FA, Viana J, Rønning OM, Faiz KW, Barra M.

PharmacoEconomics. 2019 May;37(5):715-725

EQ-5D-5L Valuation for the Malaysian Population

Shafie AA, Vasan Thakumar A, Lim CJ, Luo N, Rand-Hendriksen K, Md Yusof FA.

Quality of Life Research. 2019 May;28(5):1129-1143

A Norwegian 15D value algorithm: proposing a new procedure to estimate 15D value algorithms

Michel YA, Augestad LA, Barra M, Rand K.

Journal of Neurology. 2019 Jan;266(1):68-84

Stroke incidence in the young: evidence from a Norwegian register study

Barra M, Labberton AS, Faiz KW, Lindstrøm JC, Rønning OM, Viana J, Dahl FA, Rand K.

Value in Health. 2019 Jan;22(1):23-30

Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol

Stolk E, Ludwig K, Rand K, van Hout B, Ramos-Goñi JM.

Substance Abuse: Research and Treatment. 2019 Aug 15;13:1178221819866181

Predicting Dropout from Inpatient Substance Use Disorder Treatment: A Prospective Validation Study of the OQ-Analyst

Brorson HH, Arnevik EA, Rand K.

Value in Health. 2018 Sep;21(9):1124-1131

Quality-Adjusted Life-Years without Constant Proportionality

Craig BM, Rand K, Bailey H, Stalmeier PFM.

Value in Health. 2018 Apr;21(4):462-470

Comparing 15D Valuation Studies in Norway and Finland-Challenges When Combining Information from Several Valuation Tasks

Michel YA, Augestad LA, Rand K.

Value in Health. 2017 Jul-Aug;20(7):945-952

Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values

Rand-Hendriksen K, Ramos-Goñi JM, Augestad LA, Luo N.

Quality of Life Research. 2017 Dec;26(12):3353-3363

Comparison of health state values derived from patients and individuals from the general population

Gandhi M, Tan RS, Ng R, Choo SP, Chia WK, Toh CK, Lam C, Lee PT, Latt NKZ, Rand-Hendriksen K, Cheung YB, Luo N.

Value in Health. 2017 Apr;20(4):662-669

Estimating an EQ-5D-5L Value Set for China

Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K.

Quality of Life Research. 2016 Sep;25(9):2179-91

Influenced from the start: anchoring bias in time trade-off valuations

Augestad LA, Stavem K, Kristiansen IS, Samuelsen CH, Rand-Hendriksen K.

Health and Quality of Life Outcomes. 2016 Nov 28;14(1):164

"When I saw walking I just kind of took it as wheeling": interpretations of mobility-related items in generic, preference-based health state instruments in the context of spinal cord injury

Michel YA, Engel L, Rand-Hendriksen K, Augestad LA, Whitehurst DG.

Value in Health. 2015 Mar;18(2):217-23

Learning and satisficing: an analysis of sequence effects in health valuation

Craig BM, Runge SK, Rand-Hendriksen K, Ramos-Goñi JM, Oppe M.

Quality of Life Research. 2013 May;22(4):705-14

Time trade-off and attitudes toward euthanasia: implications of using 'death' as an anchor in health state valuation

Augestad LA, Rand-Hendriksen K, Stavem K, Kristiansen IS.

Clinical Psychology Review. 2013 Dec;33(8):1010-24

Drop-out from addiction treatment: a systematic review of risk factors

Brorson HH, Ajo Arnevik E, Rand-Hendriksen K, Duckert F.

Value in Health. 2012 Jul-Aug;15(5):777-82

Time trade-off and ranking exercises are sensitive to different dimensions of EQ-5D health states

Rand-Hendriksen K, Augestad LA.

Quality of Life Research. 2012 Aug;21(6):1005-12

Comparison of hypothetical and experienced EQ-5D valuations: relative weights of the five dimensions

Rand-Hendriksen K, Augestad LA, Kristiansen IS, Stavem K.

Quality of Life Research. 2020 Oct 6

US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples

Jiang R, Janssen MFB, Pickard AS.

Quality of Life Research. 2020 Nov 28

Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off

Jiang R, Shaw J, Mühlbacher A, Lee TA, Walton S, Kohlmann T, Norman R, Pickard AS.

Quality of Life Research. 2020 Oct;29(10):2651-2660

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings

Joseph RW, Liu FX, Shillington AC, Macahilig CP, Diede SJ, Dave V, Harshaw Q, Saretsky TL, Pickard AS.

Value in Health. 2019 Mar;22(3):267-275

Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report

Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-Séverac H, Crawford B. Cruz L, Karnon J, Lloyd A. Paisley S, Pickard AS.

Pediatric Pulmonology. 2019 Feb;54(2):179-185

Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy

Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R.

Journal of Patient-Reported Outcomes. 2017;2(1):13

Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment

Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS.

Journal of Comparative Effectiveness Research. 2018 Feb;7(2):177-180

Comparative effectiveness and patient-centered outcomes research: enhancing uptake and use by patients, clinicians and payers

Schumock GT, Pickard AS.

PharmacoEconomics. 2018 Jun;36(6):637-640

3L, 5L, What the L? A NICE Conundrum

Devlin N, Brazier J, Pickard AS, Stolk E.

Medical Care. 2017 Nov;55(11):979-984

Patient Experience-based Value Sets: Are They Stable?

Pickard AS, Hung YT, Lin FJ, Lee TA.

PLoS One. 2017 May 30;12(5):e0177323

The societal cost of heroin use disorder in the United States

Jiang R, Lee I, Lee TA, Pickard AS.

Journal of Medical Economics. 2017 Jan;20(1):19-27

EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis

Pickard AS, Gooderham M, Hartz S, Nicolay C.

Quality of Life Research. 2016 Mar;25(3):625-36

QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30

King MT, Costa DS, Aaronson NK, Brazier JE, Cella DF, Fayers PM, Grimison P, Janda M, Kemmler G, Norman R, Pickard AS, Rowen D, Velikova G, Young TA, Viney R.

PharmacoEconomics. 2015 Aug;33(8):867-77

A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)

Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D.

Journal of Managed Care & Specialty Pharmacy. 2015 Feb;21(2):114-22

Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors

Ursan ID, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS.

Journal of Comparative Effectiveness Research. 2015;4(4):359-66

Using linked electronic data to validate algorithms for health outcomes in administrative databases

Lee WJ, Lee TA, Pickard AS, Shoaibi A, Schumock GT.

Value in Health. 2012 Jul;15(5):708-15

Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS.

Seminars in Arthritis and Rheumatism. 2012 Aug;42(1):56-65

Disease-specific patient reported outcome tools for systemic lupus erythematosus

Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, Rodby RA, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori ML, Kosinsky M, Merrill JT, Weisman MH, Wallace DJ.

European Journal of Cancer. 2012 Feb;48(3):311-323

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial

Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antràs L, Neary MP, McCann L, Hodge R, Sternberg CN.

Health Services Research. 2011 Aug;46(4):1104-1123

The Impact of Medicare Part D on Out-of-Pocket Costs for Prescription Drugs, Medication Utilization, Health Resource Utilization, and Preference-Based Health Utility

Liu FX, Alexander GC, Crawford SY, Pickard AS, Hedeker D, Walton SM.

Bone Marrow Transplantation. 2011 Aug;46(8):1084-8

Outcome, toxicity profile and cost analysis of autologous stem cell mobilization

Jagasia MH, Savani BN, Neff A, Dixon S, Chen H, Pickard AS.

Archives of Internal Medicine. 2009 Aug 10;169(15):1403-10

Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease

Lee TA, Wilke CT, Joo M, Stroupe KT, Krishnan J, Schumock GT, Pickard AS.

Medical Care. 2009 Feb;47(2):176-83

Proxy assessment of HRQL in African American and white respondents with prostate cancer: the importance of perspective

Pickard AS, Lin HW, Knight SJ, Hung S-Y, Chang C-H, Sharifi R, Bennett CL.

Health and Quality of Life Outcomes. 2007 Dec 21;5:70

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

Pickard AS, Neary M, Cella D.

Medical Care. 2007 Sept;45(9):812-819

Evaluating Equivalency Between Response Systems: Application of the Rasch Model to a 3-Level and 5-Level EQ-5D

Pickard AS, Kohlmann T, Janssen MF, Bonsel G, Rosenbloom S, Cella D.

The European Journal of Health Economics . 2014 Dec;15(9):917-25

Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain

Hidalgo-Vega A, Ramos-Goñi JM, Villoro R.

BMC Musculoskeletal Disorders . 2011 Dec 21;12:287

Avoidable costs of physical treatments for chronic back, neck and shoulder pain within the Spanish National Health Service: a cross-sectional study

Serrano-Aguilar P, Kovacs FM, Cabrera-Hernández JM, Ramos-Goñi JM, García-Pérez L.

Obesity Surgery. 2014 Dec;24(12):2061-8

Cost-Utility Analysis of Gastric Bypass for Severely Obese Patients in Spain

Castilla I, Mar J, Valcárcel-Nazco C, Arrospide A, Ramos-Goñi JM.

The Stata Journal. 2016;16(3):691-701
doi: NA

eq5dds: A command to analyze the descriptive system of EQ-5D quality-of-life instrument

Ramos-Goñi JM, Ramallo-Fariña Y.

Value in Health. 2018 Feb;21(2):229-238

Choice Defines Value: A Predictive Modeling Competition in Health Preference Research

Jakubczyk M, Craig BM, Barra M, Groothuis-Oudshoorn CGM, Hartman JD, Huynh E, Ramos-Goñi JM, Stolk EA, Rand K.

Health Policy. 2019; Vol 123(2): 152-158

Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?

Lopez-Bastida J, Ramos-Goni JM, Aranda-Reneo I, Trapero-Bertran M, Kanavos P, Rodriguez Martin B.

Gaceta Sanitaria. 2020 Jan-Feb;34(1):91-95

Application of two-part models and Cholesky decomposition to incorporate covariate-adjusted utilities in probabilistic cost-effectiveness models

Arrospide A, Ramos-Goñi JM, Pechlivanoglou P, Mar J.

The Patient - Patient-Centered Outcomes Research . 2020 Jun;13(3):317-325

A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective

Louis E, Ramos-Goni JM, Cuervo J, Kopylov U, Barreiro-de Acosta M, McCartney S, Rosenfeld G, Bettenworth D, Hart A, Novak K, Donnet X, Easton D, Saldana R, Protze K, Tzur E, Alperovich G, Casellas F.

PharmacoEconomics. 2011 Mar;29(3):239-50

Comparing Methods of Data Synthesis: Re-Estimating Parameters of an Existing Probabilistic Cost-Effectiveness Model

Oppe M, Al M, Rutten-van Mölken M.

PharmacoEconomics. 2015 Oct;33(10):985-91

Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement

Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A.

Arthritis Research & Therapy. 2016 Jun 10;18(1):135

A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis

Buisman LR, Luime JJ, Oppe M, Hazes JM, Rutten-van Mölken MP.

PloS One. 2017 Feb 2;12(2):e0171292

Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes

Vemer P, Al MJ, Oppe M, Rutten-van Mölken MP.

BMJ Open. 2019;9:e025684

Cost-effectiveness of a home-based group educational programme on renal replacement therapies: a study protocol

Redeker S, Oppe M, Visser M, Busschbach JJV, Weimar W, Massey E, Ismail S; ‘Nierteam aan Huis’ consortium.

Medical Decision Making. 2019 May;39(4):393-404

Exploring the Impact of Adding a Respiratory Dimension to the EQ-5D-5L

Hoogendoorn M, Oppe M, Boland MRS, Goossens LMA, Stolk EA, Rutten-van Mölken MPMH.

Value in Health. 2017 Mar;20(3):466-473

Quality Control Process for EQ-5D-5L Valuation Studies

Ramos-Goñi JM, Oppe M, Slaap B, Busschbach JJ, Stolk E.

Medical Decision Making. 2006;26(1):18-29

Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping

Gray AM, Rivero-Arias O, Clarke PM.

Medical Decision Making. 2010;30(3):341-54

Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome

Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R.

Value in Health. 2009;13(1):34-41

The multinational nature of cost-effectiveness analyses alongside multinational clinical trials

Rivero-Arias O, Gray A.

American Journal of Medical Genetics Part A. 2014;164(7):1648-58

Epidemiology of fragile X syndrome: a systematic review and meta-analysis

Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J.

PharmacoEconomics. 2014;32(7):693-706

Mapping EQ-5D utility scores from the PedsQL generic core scales

Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE.

PharmacoEconomics. 2015;33(10):993-1011

The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration

Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A.

Medical Care. 2017;55(7):e51-e8

Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid Approach

Ramos-Goni JM, Pinto-Prades JL, Oppe M, Cabases JM, Serrano-Aguilar P, Rivero-Arias O.

Value in Health. 2018;21(5):596-604

Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach

Ramos-Goñi JM, Craig BM, Oppe M, Ramallo-Fariña Y, Pinto-Prades JL, Luo N, Rivero-Arias O.

The Patient - Patient-Centered Outcomes Research . 2018;11(2):235-47

Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong

Wong ELY, Ramos-Goni JM, Cheung AWL, Wong AYK, Rivero-Arias O.

British Journal of General Practice. 2019;69(686):e629-e37

Patient preferences for management of high blood pressure in the UK: a discrete choice experiment

Fletcher B, Hinton L, McManus R, Rivero-Arias O.

PloS One. 2019;14(4):e0215098

Exploring women's preferences for birth settings in England: A discrete choice experiment

Fletcher BR, Rowe R, Hollowell J, Scanlon M, Hinton L, Rivero-Arias O.

Health Expectations. 2020 Feb;23(1):202-11

Preferences for interventions designed to increase cervical screening uptake in non-attending young women: How findings from a discrete choice experiment compare with observed behaviours in a trial

Campbell HE, Gray AM, Watson J, Jackson C, Moseley C, Cruickshank ME, Kitchener HC, Rivero-Arias O.

PharmacoEconomics. 2020 May;38(5):499-513

Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling

Dalziel K, Catchpool M, Garcia-Lorenzo B, Gorostiza I, Norman R, Rivero-Arias O.

Internal Medicine Journal. 2020 Dec;50(12):1538-46

Scoring system to facilitate diagnosis of Gaucher disease

Mehta A, Rivero-Arias O, Abdelwahab M, Campbell S, McMillan A, Rolfe MJ, Bright JR, Kuter DJ.

PharmacoEconomics. 2016 Oct;34(10):993-1004

EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes

Oppe M, Rand-Hendriksen K, Shah K, Ramos-Goñi JM, Luo N.

Value in Health. 2019 Aug;22(8):931-941

United States Valuation of EQ-5D-5L Health States Using an International Protocol

Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV.

PharmacoEconomics. 2020 Jul;38(7):653-663

International Valuation Protocol for the EQ-5D-Y-3L

Ramos-Goñi JM, Oppe M, Stolk E, Shah K, Kreimeier S, Rivero-Arias O, Devlin N.

The Stata Journal. Volume 11 Number 1: pp. 120-125
doi: NA

eq5d: A command to calculate index values for the EQ-5D quality-of-life instrument

Ramos-Goñi JM, Rivero-Arias O.

Value in Health. 2014 Jun;17(4):445-53

A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol

Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F.